RecruitingNCT05622409

A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma

Sponsor

National Health Research Institutes, Taiwan

Enrollment

250 participants

Start Date

Dec 29, 2022

Study Type

OBSERVATIONAL

Conditions

Primary Malignant Brain Tumors

Summary

Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with distinct epidemiological, clinical, and pathological features comparing to the other common cancer diseases. The disease rarely appears with metastatic disease at diagnosis, and with the most malignant subtype, glioblastoma, occurs with preference in mid- to old-age. For decades, primary malignant brain tumors has been known as one of the most desperate disease without successful improvement regarding of the treatment. Surgical resection is the principle for the primary treatment of gliomas. Chemotherapy and radiotherapy are often applied to patients for adjuvant therapy of surgery to pursue the treatment effect. Disappointedly, vast majority of the patients would eventually develop disease recurrence, leaving only limited choice for salvage treatment thereafter. The prognosis of these patients remains desperate, and thus a better understanding of this deadly disease is crucial for finding better therapeutic strategies for these patients.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This registry study is collecting genetic and clinical data from patients in Taiwan with a type of brain tumor called adult-type diffuse glioma (including glioblastoma), to build a comprehensive database that can improve diagnosis, treatment, and understanding of these tumors. **You may be eligible if...** - You are 20 years old or older (for consent purposes in Taiwan) - You have been diagnosed with or are suspected to have an adult-type diffuse glioma (such as glioblastoma, astrocytoma, or oligodendrocytoma) based on pathology or clinical assessment - You are willing to provide tumor tissue samples for testing - You have a life expectancy of more than 3 months and are willing to attend regular follow-up **You may NOT be eligible if...** - Your brain tumor is a different type (such as a pediatric-type or a circumscribed glioma) - You are unable or unwilling to provide a complete medical history or tumor samples - You have another active cancer that has required treatment within the past 3 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(8)

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

Shuang Ho Hospital

New Taipei City, Taiwan

China Medical University Hospital

Taichung, Taiwan

Taichung Veterans General Hospital

Taichung, Taiwan

National Cheng Kung University Hospital

Tainan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Medical University -Ministry of Health and Welfare Shuang-Ho Hospital

Taipei, Taiwan

CHANG GUNG MEMORIAL HOSPITAL, Linkou

Taoyuan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05622409